Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Scherer D
,
Hassel D
,
Bloehs R
,
Zitron E
,
von Löwenstern K
,
Seyler C
,
Thomas D
,
Konrad F
,
Bürgers HF
,
Seemann G
,
Rottbauer W
,
Katus HA
,
Karle CA
,
Scholz EP
.
???displayArticle.abstract???
Atomoxetine is a selective noradrenaline reuptake inhibitor, recently approved for the treatment of attention-deficit/hyperactivity disorder. So far, atomoxetine has been shown to be well tolerated, and cardiovascular effects were found to be negligible. However, two independent cases of QT interval prolongation, associated with atomoxetine overdose, have been reported recently. We therefore analysed acute and subacute effects of atomoxetine on cloned human Ether-à-Go-Go-Related Gene (hERG) channels.hERG channels were heterologously expressed in Xenopus oocytes and in a human embryonic kidney cell line and hERG currents were measured using voltage clamp and patch clamp techniques. Action potential recordings were made in isolated guinea-pig cardiomyocytes. Gene expression and channel surface expression were analysed using quantitative reverse transcriptase polymerase chain reaction, Western blot and the patch clamp techniques.In human embryonic kidney cells, atomoxetine inhibited hERG current with an IC(50) of 6.3 micromol.L(-1). Development of block and washout were fast. Channel activation and inactivation were not affected. Inhibition was state-dependent, suggesting an open channel block. No use-dependence was observed. Inhibitory effects of atomoxetine were attenuated in the pore mutants Y652A and F656A. In guinea-pig cardiomyocytes, atomoxetine lengthened action potential duration without inducing action potential triangulation. Overnight incubation with high atomoxetine concentrations resulted in a decrease of channel surface expression.Whereas subacute effects of atomoxetine seem negligible under therapeutically relevant concentrations, hERG channel block should be considered in cases of atomoxetine overdose and when administering atomoxetine to patients at increased risk for the development of acquired long-QT syndrome.
Alexander,
Guide to Receptors and Channels (GRAC), 3rd edition.
2008, Pubmed
Alexander,
Guide to Receptors and Channels (GRAC), 3rd edition.
2008,
Pubmed
Barker,
Acute oxcarbazepine and atomoxetine overdose with quetiapine.
2004,
Pubmed
Curran,
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
1995,
Pubmed
Ficker,
Mechanisms of arsenic-induced prolongation of cardiac repolarization.
2004,
Pubmed
Hassel,
Deficient zebrafish ether-à-go-go-related gene channel gating causes short-QT syndrome in zebrafish reggae mutants.
2008,
Pubmed
,
Xenbase
Hondeghem,
Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
2001,
Pubmed
Kiehn,
Pathways of HERG inactivation.
1999,
Pubmed
,
Xenbase
Kuryshev,
Pentamidine-induced long QT syndrome and block of hERG trafficking.
2005,
Pubmed
Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase
Rajamani,
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
2006,
Pubmed
Redfern,
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
2003,
Pubmed
Roden,
Cardiac ion channels.
2002,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Sawant,
Seizures and prolonged QTc with atomoxetine overdose.
2004,
Pubmed
Scholz,
Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation.
2005,
Pubmed
,
Xenbase
Scholz,
Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
2003,
Pubmed
,
Xenbase
Simpson,
Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
2004,
Pubmed
Spencer,
Novel treatments for attention-deficit/hyperactivity disorder in children.
2002,
Pubmed
Takemasa,
Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.
2008,
Pubmed
Trudeau,
HERG, a human inward rectifier in the voltage-gated potassium channel family.
1995,
Pubmed
Vandenberg,
The HERG K+ channel: progress in understanding the molecular basis of its unusual gating kinetics.
2004,
Pubmed
Wernicke,
An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
2007,
Pubmed
Wernicke,
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
2002,
Pubmed
Wernicke,
Cardiovascular effects of atomoxetine in children, adolescents, and adults.
2003,
Pubmed
Zitron,
Bertosamil blocks HERG potassium channels in their open and inactivated states.
2002,
Pubmed
,
Xenbase
